EyePoint completes enrollment in both Phase 3 wet AMD trials for DURAVYU; topline data mid-2026

EyePoint, Inc.

LUCIA enrolled over 400 patients in 7 months; combined LUGANO and LUCIA total over 800 patients.
DSMC interim review confirmed safety consistent with prior trials; no protocol changes, continuation recommended.
Topline 56-week data for LUGANO expected mid-2026; LUCIA topline data to follow shortly after.
DURAVYU is sustained-release TKI with 6-month redosing; evaluated vs on-label aflibercept in non-inferiority design.
Phase 3 program aligned with FDA/EMA; NDA filing targeted after one-year efficacy and safety endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.